Type 1 diabetes with residual insulin secretion (Slowly Progressive Insulin-Dependent Diabetes millitus, Latent Autoimmune Diabetes in Adults)
Conditions
Interventions
Liraglutide group Additional administration of Liraglutide injection 0.6-0.9mg per day on ongoing insulin therapy (dose of insulin can be changed) for 56 weeks
Insulin group (Control) Continue of on
Sponsors
Kitano Hospital, The Tazuke Kofukai Medical Research Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patients who have agreed to participate in this study with an informed consent 2. HbA1c <9.0%, FPG <200mg/dl, Casual PG <350mg/dl at visit 1 3. Positive for any autoimmune antibody to pancreas (GADAb, IA-2Ab) 4. Diagnosed as SPIDDM (LADA) with residual beta-cell function (C-peptide & >0.3ng/ml)
Exclusion criteria
Exclusion criteria: 1. The patients who did not agree with this study 2. The patients with serious complications 3. The patients with chronic kidney disease higher than stage 4 4. Those who are not approved to be eligible to this study by corresponding researcher or co-researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in insulin secretory response to glucagon- and arginine-stimulation test | — |
Secondary
| Measure | Time frame |
|---|---|
| Anti GADAb, Glycemic control(HbA1c, FPG/PPG, 7 points blood glucose levels in self-monitoring of blood glucose, Body weight, Hypoglycemia, Total dose of insulin injection per day, Adverse Events (including an abnormal laboratory finding) | — |
Countries
Japan
Contacts
Public ContactYoshiyuki Hamamoto
Kitano Hospital Center for Diabetes and Endocrinology
Outcome results
None listed